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Abstract
Background and purpose: It is unknown what the optimal anticoagulant level is to prevent thromboembolic
stroke in patients with left ventricular assist device (LVAD) support. We aimed to evaluate the relation between
coagulation status and the occurrence of thromboembolic stroke in HeartMate-II LVAD assisted patients.
Methods: Thirty-eight consecutive patients with a HeartMate-II LVAD were included. Coagulation status was
classified according to INR and aPTT ratio at: 1) the moment of first thromboembolic stroke; and 2) during the two
weeks preceding the first thromboembolic stroke to assess long-term coagulation status. In patients without stroke,
coagulation status was determined just before heart transplant, VAD explantation or death, whichever came first,
and at two weeks preceding these surrogate endpoints. Based on coagulation status, patients were divided in two
groups: Group I (reference group) was defined as INR below 2 and aPTT ratio below 1.5; Group II (adequate
anticoagulation) as INR above 2 or aPTT ratio above 1.5. Logistic regression analysis was performed to assess the
odds ratio for developing stroke for patients with adequate anticoagulation compared to the reference Group.
Results: Thromboembolic stroke occurred in six (16 %) patients, none within 2 weeks after LVAD implantation.
Considering coagulation status at the time of event, patients in coagulation Group II had no decreased risk for
thromboembolic stroke (OR 0.78; 95 % CI 0.12–5.0). Results for coagulation status 2 weeks prior of event could not
be calculated as all six strokes occurred in Group II.
Conclusion: In our experience anticoagulation within predefined targets is not associated with a reduced
thromboembolic stroke risk in patients with a HeartMate-II LVAD on antiplatelet therapy. However, no firm
statement about the effect of either anticoagulant or antiaggregant therapy can be made based on our study. A
larger randomized study is needed to support the hypothesis that there may be no additional benefit of coumarin
or heparin therapy compared with antiplatelet therapy alone.
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Background
Left ventricular assist devices (LVADs) have become an
increasingly important therapeutic option in the treat-
ment of end-stage heart failure. LVADs were initially
introduced as ‘bridge-to-transplantation’. However, there
is limited availability of donor organs and many patients
with end-stage heart failure are not eligible for cardiac
transplantation. Therefore, LVADs are applied as destin-
ation therapy as well, especially as outcomes for these
patients have been demonstrated to be favorable when
compared to medical therapy [1–4]. This results in more
LVAD implantations, but also in a longer duration of
implantation, which may increase the risk of complica-
tions including infections and stroke.
The reported incidence of stroke during LVAD sup-
port varies from 2 % to 47 % in studies evaluating differ-
ent types of LVADs [5–8]. Anticoagulation is widely
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used for the prevention of thromboembolic stroke in
LVAD patients, but the optimal therapeutic regime has
been a matter of debate and no generally accepted
guideline currently exists. Prophylactic administration of
anticoagulants may enhance the risk of systemic bleed-
ing and hemorrhagic stroke, which is already substantial
due to LVAD-induced thrombopenia and acquired von
Willebrand syndrome [9, 10]. It is therefore difficult to
determine which anticoagulation regime is adequate.
The purpose of the current study was to evaluate the
association between anticoagulation status and the oc-
currence of thromboembolic stroke in a single-centre
cohort of patients treated with the HeartMate-II LVAD.
Methods
Study population and data sources
The study population consisted of all consecutive pa-
tients who underwent LVAD implantation in the Utrecht
University Medical Center from 2006 until 2009. Only
patients treated with the currently most frequently used
continuous flow pump HeartMate-II LVAD were included
in the analyses.
Demographic data, as well as data on the etiology of
heart disease, the presence of risk factors for atheroscler-
osis, preoperative laboratory measurements and treat-
ment characteristics were obtained through chart review.
Long term outcome data were obtained through review
of outpatient records. Data on the occurrence of cere-
brovascular events were obtained through retrospective
re-evaluation of imaging studies, in addition to review of
clinical records and radiology reports.
In all cases, the intention of treatment with an LVAD
was bridge-to-transplantation, therefore only patients who
were eligible for cardiac transplant had LVAD implant-
ation. All patients had a New York Heart Association
(NYHA) classification IIIb or IV and received maximum
medical treatment, including intravenous inotropic sup-
port. The decision for type of assist device depended on
device availability and surgeon’s preference rather than on
patient characteristics.
Anticoagulation protocol
Patients in whom a HeartMate type-II was implanted
received acetylsalicylic acid 100 mg daily and were add-
itionally treated with heparin as soon as possible with
the aim to keep the activated partial thromboplastin
time (aPTT) ratio between 1.5–2.0, which mostly re-
sulted in an aPTT of 50–70 s. When discharge from the
ICU was within reach, usually between 1 and 2 weeks
postoperatively, acenocoumarol was started with a target
International Normalized Ratio (INR) for outpatients of
2.0–3.0. Heparin was discontinued once an INR of 2.5
had been reached. Acetylsalicylic acid 100 mg daily was
continued in all cases. Low molecular weight heparin
was not used during the study period.
Outcomes and definitions
The primary outcome for the current analysis was the
occurrence of thromboembolic stroke, including transi-
ent ischemic attack (TIA) or lacunar stroke. All cerebro-
vascular events were adjudicated by three authors (AvD,
AS, WvdB) based on clinical information (occurrence,
type of impairment, reversibility) and radiological inves-
tigations (area, size and aspect of infarction). In case of
multiple events in one patient, only the first event was
analyzed.
Coagulation status
In patients with stroke, coagulation status was deter-
mined at the time of stroke and during the two weeks
preceding the event. The latter analysis was considered
important as the onset of clot development may well be
begin days before the occurrence of a symptomatic em-
bolus. In patients without stroke, coagulation status was
determined just before heart transplant, VAD explant-
ation or death, whichever came first, and at two weeks
preceding these surrogate endpoints. In patients with
on-going LVAD-support at the time of follow-up, coagu-
lation status was based on the most recently recorded
values and values recorded during the two weeks before.
Patients were divided in two groups based on a com-
bined assessment of the INR and aPTT ratio. Group I (ref-
erence group) included patients with both INR and aPTT
ratio below the target of 2.0 and 1.5, respectively. Group II
(adequate anticoagulation) included patients with either
INR above 2.0 or aPTT ratio above 1.5. Patients who did
not receive heparin had no mandatory aPTT measure-
ments. Hence, in case of missing aPTT values they appar-
ently were not on heparin therapy and were attributed an
aPTT ratio of 1.
Statistical analysis
Continuous data were presented as median with inter-
quartile range. Categorical data were presented as per-
centages. Differences between patients with different
coagulation status were tested with the Fisher’s Exact
test for categorical variables, and with the Mann-Whitney
U-test for continuous variables that were not normally
distributed. We imputed missing coagulation parameters
using single imputation with the linear regression method
with addition of a random error term. In 18 % of patients
one or more values were missing, although not necessarily
within two weeks preceding an event. The mean fre-
quency of coagulation measurements within the two week
preceding the event was 4.4 (STD 4.6). The occurrence of
stroke was presented as both cumulative incidences (i.e.
the percentage of patients with stroke for each category),
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and incidence rate (i.e. number of events per patient-
years). Univariate logistic regression analysis was per-
formed to assess the odds ratio for developing stroke for
the two different categories of coagulation status at the
time of the event. Group I was used as the reference cat-
egory. All baseline characteristics were considered poten-
tial confounders [Table 1]. The influence of potential
confounders was investigated by conducting multiple bi-
variate analyses. Any confounder that influenced the odds
ratio for developing stroke by >10 % in the bivariate
analyses was included in the multivariate model. Similar
analyses were performed for mean coagulation status dur-
ing the two weeks preceding the event. Kaplan-Meier
curves for the two categories of coagulation status at the
event were constructed. A p value < 0.05 (two sided) was
considered to be statistically significant.
Ethics
The study complies with the Declaration of Helsinki and
good clinical practice guidelines. We obtained ethics
committee approval from the University Medical Center
Utrecht. Written informed consent was waived by the
ethics committee. Patient information was anonymized
and de-identified prior to analysis.
Results
Patients
From 2006 through 2009 a total of 41 consecutive pa-
tients underwent a HeartMate-II LVAD implantation in
our hospital. Three patients were excluded from the pri-
mary analysis on thromboembolic stroke; one suffered
hemorrhagic stroke (aPTT ratio at that time was 2.60),
one post-anoxic stroke, and one symptomatic MELAS
(mitochondrial myopathy, encephalopathy, lactate acid-
osis and stroke like episodes). Tables 1 and 2 show the
baseline characteristics and clinical course data for the
remaining 38 patients. Over one-fifth of patients required
preoperative mechanical circulatory support with an intra-
aortic balloon pump or a temporary VAD (e.g. Impella
percutaneous left ventricular assist device). Median dur-
ation of support was 279 days (IQR 134 – 540); median
duration of follow-up was 275 days (IQR 75 – 522).
No patients underwent concomitant RVAD-implantation.
Complication rate for tamponade, rethoracothomy and
gastro-intestinal bleeding was higher in Group II, but due
Table 1 Baseline characteristics according to coagulation status: Group I (low anticoagulation status) included patients with both
INR below 2.0 and aPTT ratio below 1.50; Group II (adequate anticoagulation status) included patients with either INR≥ 2.0 or aPTT
ratio ≥ 1.50
Overall Coagulation status at the time of event Coagulation status two weeks prior of event
(n = 38) median (Q1-Q3) Group I (n = 12) Group II (n = 26) p Group I (n = 8) Group II (n = 30) p
Age 45 (36–54) 46 44 .94 45 45 .71
Male sex (%) 25 (66 %) 7 (58 %) 18 (69 %) .71 4 (50 %) 21 (70 %) .41
Smoking (%) 24 (63 %) 7 (58 %) 17 (65 %) .73 6 (75 %) 18 (60 %) .68
Diabetes (%) 2 (5 %) 1 (8 %) 1 (4 %) .54 0 2 (7 %) 1.0
Hypertension (%) 4 (11 %) 0 4 (15 %) .29 0 4 (13 %) .56
Hypercholesterolemia (%) 10 (26 %) 4 (33 %) 6 (23 %) .69 3 (38 %) 7 (23 %) .41
Prior MI (%) 5 (13 %) 1 (8 %) 4 (15 %) .99 2 (25 %) 3 (10 %) .28
Prior stroke (%) 4 (11 %) 2 (17 %) 2 (8 %) .58 0 4 (13 %) .56
Ischemic heart disease (%) 12 (32 %) 3 (25 %) 9 (35 %) .71 5 (63 %) 7 (23 %) .08
Hemoglobin 7.2 (6.5–7.9) 7.0 7.5 .23 6.4 7.4 .10
Leukocyte count 10.8 (8.3–13.9) 10.2 10.8 .75 8.5 10.8 .18
Platelet count 219 (164–296) 168 226 .34 192 226 .77
Creatinin 117 (96–150) 103 120 .11 119 114 .54
Blood urea nitrogen 10.6 (7.4–15.3) 90 11.8 .15 9.2 11.8 .31
ASAT 66 (32–192) 42 77 .24 126 62 .99
ALAT 71 (38–216) 53 77 .31 64 71 .57
LDH 481 (297–726) 354 542 .04 465 504 .68
Cardiac index 1.78 (1.50–2.01) 1.81 1.70 .77 1.86 1.69 .45
IABP treatment (%) 4 (11 %) 2 (17 %) 2 (8 %) .58 1 (13 %) 3 (10 %) .99
Temporary VAD (%) 4 (11 %) 2 (17 %) 2 (8 %) .58 2 (25 %) 2 (7 %) .19
Concomitant RVAD 0 0 0 - 0 0 -
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to low numbers didn’t reach statistical significance. Half of
these complications occurred in the first 48 h after im-
plantation, and two-third occurred within the first week.
Coagulation status
At the time of the primary or surrogate event, the refer-
ence Group I consisted of 12 patients and Group II con-
sisted of 26 patients. When calculating mean coagulation
during the two weeks preceding the event, 8 patients fell
into Group I, and Group II consisted of 30 patients. The
duration of sub-therapeutic anticoagulation range from
several hours to one week. No differences were demon-
strated between these groups with regard to baseline char-
acteristics, in particular in pre-LVAD right ventricular
failure, which parameter was previous associated with
stroke development [11].
Thromboembolic stroke
Overall, 6 thromboembolic strokes occurred in 6 patients
(16 %). All occurred after 14 days after LVAD implantation
or later. Median time of stroke occurrence was 43 days
(IQR 14–440) after LVAD implantation. In general, more
strokes occurred in Group II compared with the reference
Group I [Table 2] [Fig. 1].
Considering the analysis for coagulation status at the
time of stroke, the Kaplan-Meier estimates for 1-year
stroke free survival were 100 % for patients in Group I
and 84 % for patients in Group II [Fig. 2]. When coagu-
lation status was based on the two weeks preceding the
event the Kaplan-Meier estimates for 1-year stroke free
survival were 100 % for patients in Group I and 86 % in
Group II [Figs. 3 and 4].
Compared with reference Group I, the adjusted odds ra-
tio for the development of thromboembolic stroke was
0.53 (95 % CI 0.06–4.6) for coagulation Group II [Table 3].
When coagulation status was based on the two weeks pre-
ceding the event, the odds ratio could not be calculated as
all strokes occurred in patients with adequate anticoagula-
tion (Group II).
Discussion
The main finding from our study is that patients assisted
by a HeartMate-II LVAD with an INR or aPTT above
predefined targets did not have a reduced stroke inci-
dence. Another important finding was that there was a
trend towards more early complications, e.g. rethora-
cothomy and gastrointestinal bleeding, in patients with
adequate anticoagulation.
It is widely assumed that the optimal INR to minimize
the risk of both thromboembolic and hemorrhagic events
needs to be between 1.5 and 2.5, in addition to the use of
aspirin. A study in out-patients showed that the risk of
thrombotic events increased when the INR was below 1.5,
whereas the risk of hemorrhagic events sharply increased
Table 2 Clinical course and outcome according to coagulation status: Group I (low anticoagulation status) included patients with
both INR below 2.0 and aPTT ratio below 1.50; Group II (adequate anticoagulation status) included patients with either INR≥ 2.0
or aPTT ratio≥ 1.50
Overall (n = 38) Coagulation status at the time of
event
Coagulation status two weeks prior
of event










Tamponade 6 (16 %) 0 6 (23 %) .15 1 (13 %) 5 (17 %) .99
Rethoracothomy 7 (18 %) 0 7 (27 %) .07 1 (13 %) 6 (20 %) .99
Infection 9 (24 %) 2 (17 %) 7 (27 %) .69 2 (25 %) 7 (23 %) .99
GI bleeding 2 (5 %) 0 2 (8 %) .99 0 2 (7 %) .99
RV failure 8 (21 %) 2 (17 %) 6 (23 %) .99 2 (25 %) 6 (20 %) .99
AKI 2 (5 %) 1 (8 %) 1 (4 %) .54 1 (13 %) 1 (3 %) .38
Median duration of follow-up in days (Q1-Q3) 275 (75–522) 299 242 .94 314 254 .96
Median duration of LVAD support in days (Q1-Q3) 279 (134–540) 321 279 .96 314 279 .97
Death before transplant 4 (11 %) 1 (8 %) 3 (12 %) .99 1 (13 %) 3 (10 %) .99
Transplanted and alive 9 (24 %) 2 (17 %) 7 (27 %) .69 1 (13 %) 8 (27 %) .65
Transplanted and deceased 1 (3 %) 0 1 (4 %) .99 0 1 (3 %) .99
Weaned from LVAD 3 (8 %) 0 3 (12 %) .54 1 (13 %) 2 (7 %) .99
On-going LVAD support 21 (55 %) 9 (75 %) 12 (46 %) .16 5 (63 %) 16 (53 %) .71
Thromboembolic stroke 6 (16 %) 2 (17 %) 4 (15 %) .99 0 (0 %) 6 (20 %) <.001
Stroke rate during LVAD support (event/patient/year) .160 .169 .156 .99 - .173 <.001
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with an INR above 2.5 [6]. One important limitation of
that study is that INR levels were recorded only at
monthly intervals and at the time of a clinical event,
whereas INRs for outpatients can change widely and over
much shorter time periods according to patient condi-
tions. Furthermore, patients were not included in the
study until they were successfully discharged. Thus, pa-
tients who had peri-operative bleeding or thrombo-
embolic events before discharge that was not related
to the degree of oral anticoagulation were excluded.
Also, numbers were very low within this sub-study in
out-patients only and no statistics were performed to
show that the numbers were statistically significant [6].
Several other studies also found that suboptimal antic-
oagulation was associated with neurological events, but
it all concerns observational studies with low absolute
numbers and several other risk factors were identified
[12, 13]. Another limitation is that a single measurement
below the target value, often at the moment stroke oc-
curred, was used for analysis. Moreover, hemorrhagic
stroke was associated with increased coagulation status
which is the reason for some to advocate a mild anticoa-
gulation protocol [14].
A limitation of our study is its retrospective design,
withholding an increased risk of missing values. To over-
come this problem several measures were taken. Firstly,
the INR was, when appropriate, calculated from the PT
ratio and the aPTT ratio from the heparin ratio. How-
ever, although the mentioned tests are related, each
marker is calculated using different types of reagent and is
therefore not freely interchangeable. The results of these
calculations must therefore be seen as estimates. Secondly,
our hospital protocol commands aPTT (or heparin ratio)
being measured 4 times daily when heparin is adminis-
tered. As a consequence, if an aPTT or heparin ratio value
was unknown, it was presumed that the patient had no
heparin therapy at that time and an aPTT ratio of 1 was
filled in. However, in outpatients on coumarin, INR mea-
surements are performed with larger intervals and there-
fore a missing value at a certain moment does not exclude
coumarin therapy. To overcome this, an imputation pro-
cedure was performed to fill in the remaining blanks. Data
Fig. 1 Thromboembolic stroke incidence according to coagulation status at event. Patients within Group I are positioned in the square in the
lower left hand corner; Group II consists of the 3 squares that enclose Group I. O = no thromboembolic stroke. * = thromboembolic stroke
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omission rarely occurs at random, but is often related to
other observed patient characteristics. Excluding subjects
with missing values not only leads to loss of statistical
power, but also to biased results [15–17]. To decrease bias
and increase statistical efficiency, we therefore chose to
impute missing values, rather than to perform complete-
case analyses.
Another possible limitation is that although many risk
factors were assessed, we didn’t systematically collect
pre-implant atrial fibrillation or the CHA2DS2-Vasc
score in our patients, which is associated with a higher
risk of thromboembolic events in patients with continu-
ous flow LVAD [18]. None of the 6 stroke patients had
atrial fibrillation at the time of stroke, so the impact on
our results is limited.
Throughout the study period various models of LVAD
have been used and results of this study may not be
translated to the other used devices. We chose to restrict
the analysis to one particular LVAD type (i.e. Heart Mate
II) to rule out that the observed differences in thrombo-
embolic events were due to the different type of LVAD
used.
The three patients with primary intracranial hemor-
rhages, global ischemia and MELAS, were left out of the
case control analyses, because these events are not related
to thromboembolism. The low incidence of intracranial
Fig. 2 Thromboembolic stroke incidence according to coagulation status 2 weeks prior to event. Patients within Group I are positioned in the square
in the lower left hand corner; Group II consists of the 3 squares that enclose Group I. O = no thromboembolic stroke. = thromboembolic stroke
Table 3 Influence of coagulation status on the occurrence of





At the time of event:
Coagulation status I - (reference) -
Coagulation status II 0.91 (0.14 – 5.8) 0.63 (0.07 – 5.5)a
Two weeks prior of event:
Coagulation status I - (reference) -
Coagulation status II N/Ab N/Ab
Results are presented as odds ratios with 95 % confidence intervals (CI)
aAdjusted for age, history of hypertension, history of hypercholesterolemia,
ischemic heart disease
bCould not be calculated as all strokes occurred in patients assigned to
Group II
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hemorrhage, however, may indicate that anticoagulation
with coumarin or heparin does not lead to an increased
risk of intracranial hemorrhage. It is well known that dual
or triple therapy increase the risk of bleeding complica-
tions [19]. This is further illustrated by the higher inci-
dence of tamponade and rethoracothomy in the group of
patients with adequate anticoagulation status.
To our knowledge, no randomized clinical trial on antic-
oagulation in patients with VAD, has ever been performed.
We have previously performed a systematic review on the
relation between anticoagulation protocols and occur-
rence of stroke after LVAD implantation, in which we
found that platelet aggregation inhibitors are the most
important in preventing thromboembolic stroke and
should be part of the anticoagulation protocol [20]. The
World’s Longest-Supported HeartWare Ventricular Assist
Device Patient has been managed on low-dose aspirin
(100 mg three times per week) without thrombotic com-
plications [21].
Based on the results of our study it is not clear if post-
operative heparin decrease the number of thrombo-
embolic strokes in patients with a HeartMate-II support.
Since heparin therapy may increase the risk of short-term
systemic bleeding complications these findings indicate
that the postoperative use of heparin after HeartMate II
implantation may be refrained or postponed in selected
patients with an anticipated increased bleeding risk.
Although not undoubtedly effective in preventing long
term stroke in our study, the recently reported multicen-
ter increase in the incidence of pump thrombosis with
the HeartMate II LVAD may be an additional reason
apart from patient characteristics to maintain anticoagu-
lation with coumarins [22]. Both in-patient and device
complication remains a challenge for bioengineering,
Fig. 3 Kaplan-Meier survival curves showing stroke free survival according to coagulation status at event (Fig. 3). ______ Group I ………. Group II
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which advances may be even more important than anti-
coagulants regimes as preclinical studies in LVAD tech-
nology demonstrates that design changes may offer a
more robust alternative to antiplatelet drugs [23]. Within
the study population, no LVADs needed to be replaced,
so probably there was no occurrence of (significant)
pump thrombosis, but unfortunately we didn’t systemat-
ically assessed this endpoint.
The suggestion from the results of our study that anti-
platelet therapy could be sufficient without the addition of
coumarins should be supported by larger studies, and
more important by a qualitative assessment of the coagu-
lation status such as thromboelastometry and platelet
function assays besides the classical parameters INR, PTT,
and platelet count. With such information, it would be
possible to calibrate the antithrombotic therapy, deciding
dose variation or withdrawal of either anticoagulant or
antiaggregant therapy, on a mechanistic basis.
Conclusion
Thromboembolic stroke remains a feared complication in
patients assisted by a HeartMate-II LVAD. A vast majority
of strokes occurred despite adequate anticoagulation ac-
cording to the protocol of our institute. Methodological
shortcomings of our study prevent a firm statement on
the effect of coumarin or heparin in addition to antiplate-
let therapy. It is currently unclear how stroke can be pre-
vented in this patient category. A randomized clinical trial
is warranted in order to improve outcome of this frail and
growing patient category.
Abbreviations
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Fig. 4 Kaplan-Meier survival curves showing stroke free survival according to coagulation status 2 weeks prior to event (Fig. 4). ______ Group I
………. Group II
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